We next examined the effect of the CXCR1/2 inhibitor Reparixin on the IL-8–mediated increase in Oct4, Sox2, and Nanog expression and self-renewal of CD44hi IPF MPCs. This evidence concerns the gene CXCR1 and idiopathic pulmonary fibrosis.